Form 4: Zentalis CEO Sells Shares for Tax Obligations

Zentalis Pharmaceuticals CEO Julia Marie Eastland sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Julia Marie Eastland, CEO & President and a Director of Zentalis Pharmaceuticals, Inc. (ZNTL), reported sales of common stock.
• The sales were made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of previously granted restricted stock units.
• On February 6, 2026, 7,866 shares of common stock were sold at a price of $2.4297 per share.
• Following this transaction, Ms. Eastland beneficially owned 80,022 shares directly.
• On February 9, 2026, an additional 889 shares of common stock were sold at a price of $2.3929 per share.
• After the second transaction, Ms. Eastland's direct beneficial ownership stood at 79,133 shares.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary sale.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it represents a reduction in insider ownership, the non-discretionary nature of the sale for tax purposes under a 10b5-1 plan means it does not signal a lack of confidence from management.

Positives

• NA

Negatives

• Julia Marie Eastland, CEO & President, reduced her direct beneficial ownership by a total of 8,755 shares (7,866 + 889) through these sales.
• The sales occurred at prices of $2.4297 and $2.3929 per share, which are relatively low compared to historical highs for ZNTL.

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence in the industry. These transactions are typically pre-scheduled under Rule 10b5-1 plans and are not indicative of a change in management's outlook on the company's future performance.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by the CEO is minor and for a routine purpose, thus having minimal impact on shareholder sentiment or company valuation.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by the CEO to cover tax obligations associated with restricted stock unit vesting, executed under a pre-arranged Rule 10b5-1 plan. Such sales do not typically reflect a change in the company's fundamentals or management's long-term outlook. Therefore, a seasoned investor would likely maintain their current position, as this filing does not provide new information warranting a change in investment thesis.

Keywords

Zentalis Pharmaceuticals, ZNTL, Insider Transaction, Form 4, CEO, Stock Sale, Restricted Stock Units, Tax Withholding, Rule 10b5-1